rs72554309
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 1P and 4B. PP3BS2
The NM_000531.6(OTC):βc.127C>Aβ(p.Leu43Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000167 in 1,200,139 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 6 hemizygotes in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (β β ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. L43F) has been classified as Likely benign.
Frequency
Consequence
NM_000531.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
OTC | NM_000531.6 | c.127C>A | p.Leu43Ile | missense_variant | 2/10 | ENST00000039007.5 | NP_000522.3 | |
OTC | NM_001407092.1 | c.127C>A | p.Leu43Ile | missense_variant | 4/12 | NP_001394021.1 | ||
OTC | XM_017029556.2 | c.127C>A | p.Leu43Ile | missense_variant | 2/9 | XP_016885045.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
OTC | ENST00000039007.5 | c.127C>A | p.Leu43Ile | missense_variant | 2/10 | 1 | NM_000531.6 | ENSP00000039007.4 | ||
ENSG00000250349 | ENST00000465127.1 | c.172-298781C>A | intron_variant | 5 | ENSP00000417050.1 | |||||
OTC | ENST00000488812.1 | n.219C>A | non_coding_transcript_exon_variant | 2/6 | 5 | |||||
OTC | ENST00000643344.1 | n.127C>A | non_coding_transcript_exon_variant | 2/11 | ENSP00000496606.1 |
Frequencies
GnomAD3 genomes AF: 0.0000896 AC: 10AN: 111666Hom.: 0 Cov.: 22 AF XY: 0.000118 AC XY: 4AN XY: 33824
GnomAD4 exome AF: 0.00000919 AC: 10AN: 1088473Hom.: 0 Cov.: 27 AF XY: 0.00000565 AC XY: 2AN XY: 354173
GnomAD4 genome AF: 0.0000896 AC: 10AN: 111666Hom.: 0 Cov.: 22 AF XY: 0.000118 AC XY: 4AN XY: 33824
ClinVar
Submissions by phenotype
Ornithine carbamoyltransferase deficiency Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Dec 23, 2022 | This OTC variant (rs72554309) is rare (<0.1%) in a large population dataset (gnomAD: 2/21659 total alleles; 0.009%; 1 hemizygote βless than 30 years-old) and has been reported in ClinVar. A previously reported alternate pathogenic missense variant (p.Leu43Pro) occurs at this amino acid position. Of two bioinformatics tools queried, one predicts that the substitution would be damaging, while the other predicts that it would be tolerated. The leucine residue at this position is strongly conserved across the vetrebrate species accessed. Bioinformatic analysis predicts that this missense variant would not affect normal exon 2 splicing, although this has not been confirmed experimentally to our knowledge. Due to insufficient evidence that this variant is deleterious, we consider the clinical significance of c.127C>A (p.Leu43Ile) to be uncertain at this time. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 24, 2024 | This sequence change replaces leucine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 43 of the OTC protein (p.Leu43Ile). This variant is present in population databases (rs72554309, gnomAD 0.03%), including at least one homozygous and/or hemizygous individual. This variant has not been reported in the literature in individuals affected with OTC-related conditions. ClinVar contains an entry for this variant (Variation ID: 1348491). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt OTC protein function with a positive predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 04, 2023 | Variant summary: OTC c.127C>A (p.Leu43Ile) results in a conservative amino acid change located in the Aspartate/ornithine carbamoyltransferase, carbamoyl-P binding (IPR006132) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 183119 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.127C>A in individuals affected with Ornithine Transcarbamylase Deficiency and no experimental evidence demonstrating its impact on protein function have been reported. Two submitters have cited clinical-significance assessments for this variant to ClinVar after 2014, and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at